A clinical trial to study the efficacy of tofacitinib in patients of moderate to severe hidradenitis suppurativa

Efficacy of tofacitinib in moderate to severe (stage 2 and stage 3) hidradenitis suppurativa:A pilot study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075453

Enrollment

Registered

2024-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L732- Hidradenitis suppurativa

Interventions

Intervention1: tofacitinib -JAK inhibitor 5 mg twice a day: Tofacitinib 5mg twice a day, in dose adjustment according to disease severity grading ,given for 6 months , and followed up in 3 months Inte

Eligibility

Inclusion criteria

Inclusion criteria: hidradenitis suppurative- Hurley stage 2 and Hurley stage 3

Exclusion criteria

Exclusion criteria: Pregnant and lactating females history of liver disease, stroke and thromboembolic disorders Unwillingness to participation pre-existing history of cancer,HIV

Design outcomes

Primary

Measure	Time frame
Percentage of patients who achieved clinical responseTimepoint: At baseline, 24 weeks and 36 weeks	—

Secondary

Measure	Time frame
Assessment of ultrasonographic changes in severity of hidradenitis suppurativaTimepoint: baseline,6 months;response to treatment using IHS4 scoreTimepoint: base line,6 months;change in quality of life using HiSQOLTimepoint: baseline, 6 months;changes in IL 6Timepoint: baseline, 6 months	—

Countries

India

Contacts

Public ContactDr Sunil Dogra

PGIMER ,Chandigarh

sundogra@hotmail.com9855005941

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026